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Pediatric Medulloblastoma: A
Radiation Oncologist Perspective
Meenu Gupta and Mushtaq Ahmad
Abstract
Pediatric medulloblastomas are radiosensitive and mostly curable tumors if they
are non-metastasized. Postsurgery adjuvant radiation therapy remains the corner-
stone therapy in the curative intent treatment. In case of children less than three
years, pre-irradiation chemotherapy is given to defer radiotherapy till the child is
three year old. Introduction of conformal radiotherapy in addition to technical
improvements in surgery and radiotherapy, risks definition and molecular analysis
of prognostic factors has most likely contributed to the improved survival rates.
Children should ideally be referred in time to an appropriate higher center with
adequate infrastructure, expertise and radiotherapy facilities for better outcome of
the disease.
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1. Introduction
Harvey Cushing and Percival Bailey were the first who described the name
medulloblastoma as “Spongioblastoma Cerebelli” in June, 1925 for posterior fossa
tumors of preadolescents population. They reported 29 cerebellar vermis tumor in
children and young adults. Later they renamed as “medulloblastoma” as the term
“Spongioblastoma multiforme” was described by Globus and Strauss in 1925 for
various adults cerebral tumors in which feature of considerable cellular differentia-
tion was seen. This picture was found absent in tumors of cerebellar origin [1, 2].
World Health Organization (WHO) defined medulloblastoma as “invasive malig-
nant embryonal tumor of the cerebellum with commonest manifestation seen in
children”. These neuroepithelial tumors have inherent tendency to spread through
the cerebrospinal fluid to cranial and spinal subarachnoid spaces [3].
2. Epidemiology
Injuries followed by malignancy are the second leading cause of mortality among
children. After leukaemia’s, brain tumors are the most common in children
accounting for ‘25%’ of all malignancies in children [4]. Most common malignant
CNS tumor in children is medulloblastoma (MB) constituting 20% of primary brain
tumors and approximately 40% of all tumors of the posterior fossa [5]. The incidence
of medulloblastoma in adults is relatively low as compared to pediatric population. This
constitutes 1% of all CNS tumors and this may be the cause of scanty data available in
1
adult MB group [6]. U.S data showed the incidence of the medulloblastoma is 1.5–2
cases/100,000 population. Three hundred and fifty new cases in the United States are
seen each year. The peak incidence is seen in 1st decade of life and incidence is noted
higher in the pediatric age group 3–4 years followed by 8–10 years of age.
CBTRUS (Central Brain Tumor Registry of the United States) showed that inci-
dence is higher in males as compared to females (Males: 0.16 vs. Females: 0.12). But
this trend is different in children who are less than one year old. There is rising
trend of higher incidence (APC: 1.7, 95% CI0.4, 4.0) and death risk (Hazard Ratio
for Survival: 0.74 with pvalue0.09) seen in black race compared to whites which is
non-significant [7, 8].
3. Clinical presentation
There is rapid initiation of clinical symptoms are secondary to the rapid prolif-
eration of these cellular malignant tumors. Symptoms of medulloblastomas vary
with age. Earlier age of onset is associated with behavioral changes. Other symp-
toms may include listlessness, moodiness or irritability, vomiting, and lack of social
interactions. As medulloblastoma is rapidly growing tumor, this results in obstruc-
tive hydrocephalus which manifests as raised intracranial pressure (ICP). Children
may be seen with macrocephaly, fullness of fontanelle, and delayed developmental
milestones. Older children and adults have symptoms of raised intracranial pressure
like headache, vomiting, especially upon awakening in the morning hours.
Headache usually gets better during the day. As anatomical location of medullo-
blastoma is cerebellum but symptoms slightly vary within various sites of cerebel-
lum. Truncal ataxia result from tumors located in midline of cerebellum and
appendicular ataxia is associated with the hemispheric located tumors [1]. There
can be stretching of sixth cranial nerve because of hydrocephalus resulting in
double vision. Meningeal irritation causes tilting of head and stiffness of neck due to
the tonsillar herniation. Trochlear nerve palsy related to tumor compression is
another reason of head tilt. Patients with spinal metastasis had symptoms of back-
ache, weakness of bilateral lower limb and loss of bowel and bladder control.
Metastatic disease symptoms depend upon the site involvement [9]. Majority are
sporadic cases but there are associated syndromes like Gorlin syndrome (nevoid
basal-cell carcinoma syndrome), Blue rubber-bleb nevus syndrome, Rubinstein-Taybi
syndrome and Turcot syndrome (glioma polyposis syndrome) [10].
4. Management
Although radiology is good contributor of diagnosis still detailed history and
physical examination remained important and has to be done before proceeding for
any investigations. Alteration of child behavior, persistent symptoms and focal
neurological deficit are warning signs and should be proceeded with neuroimaging
for diagnosis.
4.1 Imaging
4.1.1 Computed tomographic
Computed tomographic (CT) appearance of a medulloblastoma is seen as well-
defined vermian cerebellar mass which is hyperattenuated with surrounding
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vasogenic edema and sometimes evidence of hydrocephalus is seen. Contrast
enhanced images show homogeneous enhancement.
4.1.2 MRI imaging
MRI imaging of the entire neuraxis, brain and spine is recommended for
suspected cases. MRI images show “Low-to-intermediate signal intensity” on
T1-weighted images and “moderately high signal intensity” on T2-weighted images,
compared to cerebellar white matter. Intratumoral haemorrhage, peritumoral
oedema, tonsillar herniation, hydrocephalus and calcification are other associated
findings. Multivoxel MR spectroscopy (MRS) of the primary tumor can assess the
tumor metabolites like ‘elevated Choline peaks and decreased Creatine and N-acetyl
acetate peaks’. Even without frank necrosis, a small amount of lipid-lactate peak
sometimes observed indicating an increase in metabolic activity. Due to densely
packed cells within the tumor and nuclear: cytoplasm ratio is higher, MB causes
restriction of diffusion. There is restriction of diffusion of water particles in the
tumor. So there is high signal of the tumor in diffusion-weighted MR images [11].
As frequency of spine seeding is 35% at diagnosis, to rule out any leptomeningeal
metastases, Sagittal fat-suppressed post- gadolinium contrast MRI of the spine
should be performed prior to surgery (Figure 1). Guang-Yao Wu et al. published
data showed that proton magnetic resonance spectroscopy (1H-MRS) and Diffusion
Weighted Imaging are helpful for qualitative diagnosis of medulloblastoma [12].
Baseline hearing status with tests like Audiometry, IQ Testing and hormonal
levels with Serum TSH and GH can be tested.
4.2 Neurosurgery
Mostly medium and large sized tumors in posterior fossa are associated with
hydrocephalus. In routine practice, prior to definitive surgery, ventriculo-
peritoneal (VP) shunt should generally be avoided as definitive resection of tumor
efficiently relieves the obstruction by opening the CSF pathways. Ideal surgery of
any tumor is complete surgical resection, but feasibility and safety is priority. In
Figure 1.
Showing preoperative MRI. (A) T1 weighted image post- gadolinium with tumor arising from midline of
cerebellum. (B) T2 FLAIR with mild hyper intensity and voxel showing the tumor area of interest for
spectroscopy. (C) Drop metastasis. (D) Significantly increased choline peaks with decreased NAA and Cr peaks
on Spectroscopy.
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such circumstances, it is recommended to attempt maximal safe resection and
residual disease can be left behind rather than aggressive surgical resection
approach that can precipitate significant morbidity. Benefit to risk ratio of complete
surgical removal of tumor has to be assessed preoperatively [13, 14].
4.2.1 Post surgery neuroimaging
Ideal timing of post surgery MRI imaging should be obtained immediately,
within 24–48 h of tumor resection, for accurately identification of the extent of
surgical resection and quantification of the status of the residual tumor. If immedi-
ate post surgery MRI imaging has not been obtained, then recommendation is to
wait for at least 2–3 weeks, but no more than 4-weeks, for resolution of post surgical
changes and this will further prevent false positive results. Recommendations for
timing of postoperative CSF analysis for malignant cells are also same, at least 2–
3 weeks post surgery to prevent errors like false positive results [15, 16].
4.3 Histopathology
Classification of most of the CNS tumors are still relying on only histopatholog-
ical features but in medulloblastomas, integration of additional molecular informa-
tion has updated WHO classification from 2007 to 2016. Medulloblastoma is
classified now by an integrative diagnosis including a histologically as well as
genetically defined compound as shown in Table 1 [17].
Molecular classification provides additional clinical and prognostic information
which has the potential for identification of innovative strategies and research for
the management of this disease (Table 2) [18, 19].
4.4 Staging
Medulloblastomas originally were staged only on surgical basis but “Modified
Chang Staging” is the current standard and there is addition of imaging [20]
explained in Figure 2.
Risk stratification based on clinico-radiological analysis is still widely practiced
and remains valid for Radiation planning in institutions. COG and SIOP Group
accepted the clinical prognostic variables [21] shown in Figure 3. Although with the
inclusion of molecular sub-grouping and genetic analysis of disease, more robust
information about risk stratification and outcome of disease can be concluded to
some extent but this required availability of these facilities with expertise in insti-
tutions. Incomplete neuraxis staging should be classified as high risk disease.
Histopathologically defined MB Genetically defined MB
Medulloblastoma, classic • Medulloblastoma, WNT-activated
Desmoplastic/nodular medulloblastoma • Sonic Hedgehog (SHH) activated and
TP53-mutant
• Sonic Hedgehog (SHH) activated and
TP53-wildtype
Medulloblastoma of extensive nodularity • Non-SHH/Non-WNT
Large cell/anaplastic medulloblastoma • Medulloblastoma, group 3
Medulloblastoma, not otherwise specified (NOS) • Medulloblastoma, group 4
Table 1.
WHO 2016 updated classification of medulloblastomas.
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Wingless
activated
(WNT) MB
Sonic hedgehog
(SHH) subgroup
Group 3 Group 4
Cell of origin Dorsal brainstem
(lower rhombic
lip) neuronal
progenitors
Cerebellar external
granular layer,
neuron precursors
Ventricular
zone neural
progenitors
Cerebellum progenitors
(upper rhombic lip)
Prevalence 10% 30% 25% 35%
Male:female 1:1 1:1 2:1 3:1
Common age Older children <3 year and >16
year, adult group
Infants and
children <16
year
Infants/children/adults
Histopathology Classic. In few
case, large cell
and anaplastic
Nodular desmoplastic
histology, classic,
large cell and
anaplastic
Classic, large
cell and
anaplastic
Classic, large cell and
anaplastic
Genetic
aberrations
CTNNB1
DDX3X
SMARCA4
MYCN, GLI2,
PTCH1, SUFU,
MLL2, SMO,TP53,
BCOR1, LDB1,
GABRG1
MYC, PVT1,
OTX2,
MLL2,
SMARCA4,
CHD7
OTX2, DDX31, CHD7,
SNCAIP, MYCN, CDK6
GFI1/GFI1B, MLL2,
KDM6A, MLL3, ZMYM3
Chromosome /6 3q gain, 9q loss, 10q
loss
1q gain, 5q
loss, 10q loss
Isochromosome 17q chr X
loss, 17p loss
Molecular
markers
Beta-catenin SFRP1or GAB1 MYC
activation in
50% of this
subtype
Unknown
Metastasis Rarely present Not common High 35–40% at presentation
Recurrence Rarely seen Local Metastasis Metastasis
5 year overall
survival
95% 75% 50% 75%
Future strategy Reduction in
therapy
SHH pathway
inhibitors
Intensified
therapy,
novel
therapeutics
Robust and large data
research
Table 2.
Medulloblastoma as a group of molecularly distinct subtypes.
Figure 2.
Modified Chang’s staging system.
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5. Radiation therapy
Medulloblastoma, the embryonal tumors of the central nervous system, are highly
radiosensitive tumors. After 200 cGy, the survival fraction has been reported to be
27%. Although Dargeon in 1948 stated that “medulloblastomas … have a consistently
unfavourable prognosis” but later careful observation of Edith Paterson regarding
pattern of disease spread brings hope to this disease. Radiating brain and spinal cord
in one undivided volume principle mentioned by Edith Paterson and Farr. was based
on the post-mortem findings of brain and spinal cord deposits in untreated cases. In
1953, at the Christie Hospital a five-year survival rate for children who were treated
with kV irradiation reported by Paterson and Farr was 41%. Since then the practice to
irradiate the entire craniospinal axis is universally adopted [22, 23].
After resection of tumor, entire craniospinal axis irradiation followed by whole
posterior fossa or tumor bed boost irradiation is recommended irrespective of
clinically detectable disease. Being Radiosensitive, Radiotherapy is curative up to
70% of standard risk patients. For this pediatric age group disease, linear accelera-
tors are better than telecobalt machines and these children should preferably be
referred in time to well equipped higher center with radiotherapy facility and
infrastructure to prevent unnecessary side effects. As treatment delays beyond 6–
7 weeks result in worse outcome, cobalt-60 therapy may be offered in those areas
where linacs are not available. To prevent the adverse effects of radiotherapy in the
developing nervous system, radiotherapy is avoided initially in children up to
3 years of age. CSI technique required accurate reproducibility and complex field
matching techniques. Long and complex shaped target volume homogeneity is a
technically challenging process.
Timing of radiotherapy
Improved survival for patients is associated with a shorter interval from surgery
to the start of radiation therapy. After definitive surgery, treatment should be
started within 4–7 weeks. International Society of Paediatric Oncology (SIOP) trials
showed that increase in the risk of relapse is seen if radiotherapy treatment is
delivered after 7 weeks [24].
5.1 Radiotherapy planning techniques
Younger brains are much more sensitive to damage caused by radiotherapy. CT
based conformal radiation therapy, 3DCRT, is standard of care exists for many
Figure 3.
The stratifying medulloblastoma patients clinically into high risk and standard (average) risk based on
variables like age, resection and metastasis.
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years. Patient can be in the supine or prone position during CSI treatment. Over
the years, prone position was used universally. Nowadays supine position is
used increasingly.
Advantages of supine position [25]
• Target volume coverage is more easily assured and delivery more
reproducible.
• Patient is more comfortable due to stable position.
• Technically, there is better shielding of cribriform plate and inferior temporal
lobes.
• For younger pediatric patients who require anaesthesia, there can be
better management of airways and cardiopulmonary complications can be
reduced.
Limitations of supine position
• Without adequate portal imaging, setup accuracy is difficult.
• Old couches contain metal inserts and beam entrance posteriorly through the
head rest and treatment couch is not possible.
Advantages of prone position is the junction between the spinal and cranial
fields can be better visualized.
For younger children, good sedation may be required. Expert play therapist may
help in treatment for radiotherapy without sedation.
5.1.1 Conventional planning
In 2-dimensional planning, fluoroscopic guidance two-dimensional simulation is
done. Immobilization is done with thermoplastic cast and universal prone head-rest
is used. CSI board with Lucite base plate having semicircular Lucite structures are
available for head rest and chin rest. Various degrees of neck extensions is possible
which will prevent the exit of superior border of spinal field through the oral cavity.
Chest wall can be supported by thermocols.
This complex 2-dimensional CSI technique fundamentals are:
• Two parallel opposed lateral portals for cranium and upper cervical spinal cord.
• Posterior spinal field matching with the cranial fields.
• In case of adults or larger children, matching of upper posterior spinal field
with the separate lower posterior spinal field.
Craniospinal junction can be placed at higher level: C1/C2 interspace or lower
level C5-C7. At higher level, overdose to spinal cord is low. Shoulders are excluded
from the lateral fields by keeping the craniospinal junction at lower level (C5-C7).
Also the exit dose to mandible, thyroid, pharynx and larynx is lowered. Inferior
edge of S2 is mostly the anatomical landmark where lower border of spinal field
(SF) is set. Single Craniospinal junction is set for smaller children. If length is
>36 cm, two junctions are required which are craniospinal and spinal-spinal (SS)
junction. Mostly SS junction is place at L2-L3 interspace. Multi-leaf collimators or
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custommade lead blocks are utilized for orofacial region shielding. In order to know
the divergence of spinal fields, the spinal fields are simulated first.
Various techniques used for matching craniospinal junction are:
• For matching the beam divergence of the lateral head portals with the superior
beam edge of SF, Collimator rotation is done 7–10°.
• Couch rotation 6°.
• Half beam blocks
• Asymmetric jaws
• Penumbra trimmers
The craniospinal junction should be feathering/moving weekly during craniospinal
irradiation for homogenous dose distribution and further minimizing the hot or cold
spots resulted from the gap-junction or set-up errors. With each shift, spinal field can
be extended superiorly, and cranial fields can be decreased inferiorly by 0.5–1 cm.
Similarly LB (lower border) of “superior spinal field” and SB (superior border) of
“inferior spinal” field can be shifted superiorly. This all is done for spread out of dose
homogeneity. Still the contribution of human errors is seen in many studies. As there
is direct visualization of the optical field light on the skin surface in prone position,
verification of beam delivery of CSI is relatively simple (Figure 4A) [26, 27].
The posterior fossa (PF) boost volume
Depending on the risk-stratification of the disease, volume of the posterior fossa
boost is decided. Those cases which are considered low risk and standard risk
medulloblastomas, posterior fossa target volume includes pre-operative tumor bed
with adequate margins. Most institutions add 1–1.5 cm margin to the tumor bed.
Cases of high risk and very high risk disease require irradiation of the entire poste-
rior fossa. Posterior fossa irradiation can easily be planned based on fluoroscopic
imaging in low and middle income countries where there is no availability of
multileaf collimators.
Figure 4.
(A) Gap feathering during craniospinal irradiation (CSI). Junction movement across the long treatment length
allows homogenous dose distribution by reducing the overlap hot spot and gapping cold spots. If field length <
35 cm, 100 cm SSD is used and for field length >35 cm, 120 cm SSD is used. (B) Posterior fossa boost volume
including whole infratentorial compartment.
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Conventional portals for PF boost
The PF boost is given using two lateral opposing fields. Anterior radiotherapy
borders are formed by the posterior clinoids, posteriorly by internal occipital protu-
berance, superiorly extended up to mid-point of foramen magnum and vertex (or 1 cm
above tentorium) and inferiorly extended up to C2-C3 interspace (Figure 4B) [28].
5.1.2 Conformal radiotherapy planning
In case of pediatric patients who are potential long term survivors, critical
structures are better spared by conformal techniques.
Immobilization is done in supine position and patient is aligned straight keeping
neck in the neutral position. A 4-clamp thermoplastic immobilization cast for the
head and shoulder region along with appropriate neck rest should be used. A five
point orfit for immobilization along with hyperextended head and depressed both
shoulders can result in optimal sparing of the upper esophagus and laryngeal struc-
tures.
Traditionally, axial planning images of 5 mm thickness on CT simulator from the
vertex till the upper thigh region were preferred. But in this era of high precision
radiotherapy where CTV accuracy is important for optimal outcome, CT slice
thickness is reduced in some anatomical sites of CSI field. Slice Thickness of 1–
2.5 mm from the vertex to the inferior border of third cervical vertebrae (C3) and
2–5 mm from the lower border of third cervical vertebrae (C3) to the upper ana-
tomical region of the femur should be obtained. Skull base foramina delineation is
of utmost important and for their identification, “1 mm slice thickness at the base of
skull” is preferred. To improve better identification of cranial nerves dural sheaths,
co-registration of planning imaging CT to MRI can be done [29]. CSF extensions
within the dural reflections are better demonstrated by FIESTA (Fast Imaging
Employing Steady-State Acquisition) MRI sequences [30].
Treatment volumes
Due to the risk of CSF dissemination, entire arachnoid space is included in the
clinical target volume (CTV).
5.1.2.1 Whole brain treatment volume
The frontal lobe and the cribriform plate must be included in the clinical target
volume. Inclusion of superior orbital tissue is must in the radiation field for the
adequate coverage of the frontal lobe and cribriform plate. As per SIOPE guidelines,
“the geometric edge of shielding should extend at least 0.5 cm inferiorly below the
cribriform plate and at least 1 cm elsewhere below the base of the skull”.
Delineation of CTVcranial
a. Brain along with its covering meninges are contoured till second cervical
vertebrae (C2). For outlining the inner table of the skull, CT bonywindow setting
is used with window/level: 1500–2000/300–350 suggested by SIOPE group.
b.The most critical sites are the ‘cribriform plate’, the ‘most inferior parts of the
temporal lobes’, and the ‘whole pituitary fossa’. They all to be included in the
CTVcranial delineation. For cribriform plate CT window/level suggested is
3000/400.
c. For inclusion of CSF within the dural sheath of cranial nerves, CTVcranial is
modified. For second cranial (optic) nerve, window width 350/level 40 is to be
used
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Foramina or canals of skull base which are significant for delineation of
CTVcranial are cribriform plate, optical canal of sphenoid, superior orbital fissure,
foramen ovale, internal auditory meatus (IAM), jugular foramen and hypoglossal
canal. Entire components length of the optic nerves in the CTVcranial is included in
most institutions where photons are used. But in those institutions where medullo-
blastomas are treated by protons, for prevention of any potential optical retinopa-
thy risk, only the posterior length components of the optic nerves is included
[31, 32].
As CSF flows up to the posterior aspect of eyeball which is better observed in
MRI images, it is better to include whole optic nerves in CTV in routine practice of
photon beam based radiotherapy in these cases. The cranial nerves which are
wrapped without dural cuff are the third, fourth and sixth (oculomotor, trochlear
and abducens) nerves. Nobel et al. studied the flow of cerebrospinal fluid beyond
the inner table of skull into the IAM (internal auditory meatus), juglar foramen (JF)
and hypoglossal canal (HC). Their study (on basis of 96 FIESTA MRI sequences)
concluded that the CSF extension was up to ‘16 mm’ in the internal auditory meatus
which is not very far away from the cochlea. So the cochlear sparing by CSF
exclusion within the internal acoustic canal should not be attempted. Their data also
showed that the CSF extension was up to 11 mm in the juglar fossa from inner table
of skull. There is no extension of CSF within these dural sheaths outside the outer
table of the skull. It is not so easy to delineate dural sheath CSF on MRI but CT
images with 1 mm thickness along the base of skull can show skull foramina and
canals and they can easily be contoured on bony windows (Figure 5) [29].
Figure 5.
Showing conformal planning. (A) Cribriform plate is in close proximity to ocular structures. Shielding edge
should be at least 0.5 cm below the cribriform plate and 1 cm elsewhere below base of skull to cover the temporal
fossa and skull base foramina. (B) The petrous part of temporal bone showing Internal acoustic canal (IAC).
(C) Various skull base foramina contoured in CTVcranial including dural cuffs of cranial nerves. (D)
Cribriform plate must be in target volume. (E) Entire subarachnoid space, including nerve roots laterally must
be included in CTVspinal. SFOP, French Paediatric Oncology Society; CP, cribriform plate; SOF, superior
orbital fissure; FO, foramen ovale.
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Issues of the cribriform plate (CP)
According to a 1982 report from MSKCC, 15% of recurrences are subfrontal in
medulloblastomas [33]. Hypothesis given by Donnal et al. was that the pooling of
cells secondary to gravitational effect of prone position with maximum shielding of
eyes can result in the recurrences at the region of cribriform plate [34].
5.1.2.2 CTVSpinal
The CTVSpinal (spinal target volume) includes the complete dural or thecal sac.
Lateral extension of delineation is must to cover the intervertebral or neural foramina
with their exiting nerve roots from the C2 cervical spine till the lower end of the
thecal sac. Lower border of CTVSpinal is appreciated by the latest spinal MRI imaging.
Children Oncology Group (ACNS0332, ACNS 0331, ACNS 0122) recommended the
inferior border of CTVSpinal is ‘2 cm below the termination of the subdural space’ which
is usually at bottom of second sacral vertebrae. The other SIOPE group trials
recommended that the lower border of CTVSpinal must be determined by the spinal
MRI imaging of the termination of the thecal or dural sac. This border should be
kep. 1 cm inferior to this. Root canals in the Sacral CTVSpinal can be excluded. This
recommendation is based on a MRI study conducted on ten volunteers who were
healthy proved that there was no CSF around the nerve roots of sacral segments.
If patients are to be treated by protons, then for skeletally immature patients,
CTVSpine should include the vertebral bodies. This will decrease the risk of unequal
vertebral growth. In skeletally mature patients, spinal TV should include the sub-
arachnoid space of spine with a margin of 3–5 mm is summed up to the body of
vertebrae for set up uncertainties/variation (interfraction) [29].
Delineation of posterior fossa boost volume
High Risk and Very High Risk disease: The clinical target volume PF (CTVPF)
boost encompassed the whole PF. The boost CTVPF extends superiorly up to the
tentorium cerebelli, inferiorly to the foramen magnum, and posterolaterally to the
occipital bony walls and temporal fossa. BS (Brain Stem) anterior border and mid-
brain cover the components of the posterior fossa anteriorly. The geometric margin
of 0.5 cm around the CTVPF is taken for delineation of the PTV posterior fossa
(PTVPF). PTVPF is limited to the bony confines of the skull, except at the foramen
magnum where it extended to the level of C1. The PTVPF contoured anteriorly up to
the posterior clinoids and inferiorly to the C1-C2 junction. PTV is modified at sella
and pituitary gland is excluded from anterior extension of PF boost planning.
For low risk and standard risk, tumor bed, as defined on CT images, delineation
with a margin of 1–2cm is recommended. For three-dimensional planning, two lateral
opposing portals with editing/shaping using the multileaf collimators (MLCs) is
recommended. Finally, these craniospinal and boost plans must be summated to
produce a composite treatment plan and final dose-distribution is calculated [35, 36].
5.2 Intensity modulated radiotherapy for CSI
Children and adults are two different groups as far as radiotherapy treatment in
medulloblastoma is concerned. Proliferating tissues are more in children as
CTV brain: brain and its covering meninges till lower border of C2.
PTV brain: 5 mm isotropic margin around CTV brain.
CTV spine: entire arachnoid space with nerve roots.
PTV spine: 5–8 mm isotropic margin is recommended around the CTV-spine
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compared to the adults. IMRT for adult population is a used as a routine practice for
numerous malignancies but for pediatric patients, IMRT has to be used with great
caution in view of low dose volumes. Spinal irradiation during CSI results in
increased doses delivered to anterior thoracic and abdominal structures with con-
ventional plans. Parker et al. published data showed that the PTV and dose homo-
geneity was better for the medulloblastoma CSI, IMRT plans. Dosimeteric analysis
showed V95% for IMRT was 100%, 3D planning was 96% and 2D planning was 98%.
Also V107% for IMRT was 3%, 3D planning 38% and 2D was 37%. The IMRT plans
provided better sparing of heart and liver in terms of V (10 Gy) and above. Integral
Dose analysis showed the IMRT plans were superior for liver and heart and the 3D
plan were better for the body contour. Tomotherapy may be helpful in reducing
high dose regions in OAR, but low dose of radiation to a large volume is a concern
for pediatric patients [37].
IMRT planning
IMRT for craniospinal irradiation in adult medulloblastomas is delivered after
summation of PTV brain plan and PTV spine plan. Usually the spinal PTV planning
is done first with ‘inverse planning technique’ using the 5 posterior fields with 0°,
20° and 50°gantry angles. For the craniocaudal direction, the isocenter is kept at
the “geometrical center of the PTV_spine”. For the depth and lateral position, it is
usually set at the “midline and midplane” at the level of the interphase of second
and third cervical vertebral body. Dose prescription and normalization is to the
isocenter of the spine. For the cranial target, a separate plan is created. Cranial fields
isocenter is set at the inferior most slice of the PTV brain. MLC positions can be
modified for dose reduction to the nearby OARs and adequate coverage of the
target volume. The geometric center of the PTV_brain is defined as the reference
point for dose prescription and normalization. Final composite plan for the whole
cranio-spinal axis is obtained after dosimetrically summation of spinal and cranial
plans. For taller patients, for upper and lower spine, IMRT plans are created sepa-
rately [38].
Intensity modulated radiotherapy for posterior fossa boost
Meenu et al. re-planned seven previously irradiated patients of MB with seven
field inverse planning IMRT for whole posterior fossa boost. Equidistant gantry
angles (0°, 50°, 100°, 150°, 210°, 260°, 310°) were used with step and shoot IMRT
on 6MV energy LINAC. Treatment isocenter was set at the geometrical center of the
planning target volume. They compared with 3DCRT plan delivered by two lateral
opposing beams with multileaf collimators for shaping. Their dosimeteric results
showed there were decreased mean dose to most critical organ at risk, cochlea, with
IMRT compared to the three dimensional radiotherapy plans with significant p
values i.e. 0.032 for the cochlea of right ear and 0.020 for the left sided cochlea
(Figure 6) [35] Similar results are found in published clinical studies conducted by
Huang et al. where 13% of the IMRT group had grade 3 or 4 hearing loss as
compared to 64% for the conventional group [39].
Organ at risk
OAR as demarcated on axial CT images include brain, eyes, lens, optic nerves,
optic chiasma, cochlea, parotids, mandible, thyroid, esophagus, lungs, heart,
breasts, liver, kidneys, bowel bag, rectum, bladder, gonads (ovary or testes),
vertebral bodies, uterus plus pelvis (red bone marrow).
5.3 Radiotherapy doses
Berry et al. reported a five year survival rate of 47% with lesser doses and ten
year DFS of 77% once the posterior fossa doses delivered were >52 Gy [40].
Abacioglu et al. showed in adult medulloblastomas, control rate was 33% at 5 year
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with doses <54 Gy native to 91% in those patients on whom higher doses were
delivered [41]. CSI dose reduction is feasible with the addition of chemotherapy as
level 1 evidence based data released by Children’s Cancer Study Group showed that
the reduction of doses from 36- to 23.4 Gy resulted in significantly higher risk of
recurrences outside the posterior fossa [42].
Radiotherapy doses to CSI depends upon the risk stratification of the disease at
presentation. If risk stratification or accurate staging is incomplete then patient can
be treated as high-risk disease. Radiation therapy doses according to the risk strat-
ification are shown in Table 3 [43]. There are different long term toxicities between
the adult and children. CSI dose reduction approach is avoided for adult patients.
Still big data is required to justify the addition of adjuvant chemotherapy to radio-
therapy in average risk adult patients as data showed that 70–80% of these patients
have no progression of disease at 5 years when RT is used as a sole modality. Also
there are issues of hematological toxicities in adult patients.
5.4 Proton therapy
Pediatric age is more sensitive to radiation induced carcinogenesis as compared
to adults by a factor of at least 10 [44].
As children anatomy is small so critical organs are very much close to the target
volume. Also the scatter from the treatment volume is highly significant in children
having small body area as compared to large body of adults. Particle beam therapy is
a potential powerful tool for improving the therapeutic ratio. Goal of pediatric
radiation oncologists is integral dose minimization to whole body and organs at risk.
Advantage of protons over the photons is that they can modulate the dose to avoid
very close OARs. For CSI, advantages of protons are because of absorption of low
dose on tissue entry and the point of maximum dose deposition at the Bragg-peak.
This results in the avoidance of dose deposition to anterior organs like thyroid,
lungs, heart, gut, liver, esophagus, kidneys and urinary bladder. Also critical brain
structures such as the lens, optic chiasma, pituitary, cochleae are better spared.
Figure 6.
Coursey JCRT. Meenu et al. mid-axial dose distributions with (a) 3DCRT (b) IMRT for one of the
representative case of entire posterior fossa boost. Yellow represents 100%, red 95% and blue 70% of the isodose
lines. IMRT is advantageous over 3DCRT for cochlear sparing. 3DCRT, three dimensional conformal
radiotherapy; IMRT, intensity modulated radiotherapy.
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In grown up children, sparing the anterior portion of the vertebral body results in
minimization of bone marrow dose (Figure 7).
Consensus report from the Stockholm pediatric proton therapy conference
showed that treatment of choice for medulloblastoma is proton therapy [45]. Based
on the review of the existing theoretical and early clinical outcomes evidence,
results showed that proton craniospinal irradiation provide similar control of tumor
with potentially decreased doses to the normal structures thus reduces the risk of
side effects when compared with photon existing data [46]. Spot-scanned intensity-
modulated proton therapy (IMPT) is advantageous over the photon therapy in
terms of all radiobiological risk estimation [47].
Weight changes in medulloblastoma and adaptive proton therapy are coming up
but at present there is scanty data available. Patient selection is of utmost important
in proton therapy. Limitations of patients with their families to travel in these
Various risk
stratification
Volume and doses of radiation therapy Concurrent or adjuvant
chemotherapy
High risk and
very high risk
disease
CSI: 36Gy/ 20 fractions, 5 days a week
Boost to posterior fossa: 19.8Gy/ 11
fractions, 5 times/week
Gross metastatic deposits: Boost dose of
5.4–9 Gy/3–5 fractions
Concurrent carboplatin followed by
adjuvant six cycles of systemic
chemotherapy
Standard risk Children <18 year
CSI: 23.4Gy/13 fractions, 5 days a week
Boost to whole posterior fossa (or tumor
bed): 30.6Gy/17 fractions, 5 times/week
Adults
CSI: 36Gy/20 fractions, 5 days a week
Boost to posterior fossa: 19.8Gy/11 fractions,
5 times/week
Children <18 year
Weekly vincristine followed by
adjuvant six cycles of systemic
chemotherapy
Low risk CSI: 23.4Gy/13 fractions, 5 days a week
Boost to whole posterior fossa (or tumor
bed): 30.6Gy/17 fractions, 5 times/week
Reduced intensity chemotherapy
Table 3.
Radiotherapy doses according to risk stratification.
Figure 7.
CSI Schematic Model. (A) Photons are absorbed and secondary electrons have large range in mm resulting in
doses beyond the target volume. (B) Advantage of stopping of protons is due to the Bragg peak curve resulting in
lower doses to OARs with proton therapy.
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centers, the proton center capacity to treat children and the availability of expertise
and support structures must be evaluated by the referral physicians.
6. Chemotherapy
Chemotherapy is integral part of treatment and in standard risk cases CSI doses
can be reduced. Children less than 3 years, chemotherapy is recommended till the
child will attain the age of 3 years. Drugs like carboplatin, cyclophosphamide and
etoposide is recommended. There are various regimens recommended (Box 1). In a
published database analysis of medulloblastoma children (n = 816) age 3–8 years
who received adjuvant chemotherapy after surgery, overall rate of RT deferral after
surgery was 15.1%. Their practice was associated was decreased overall survival in
this pediatric population even in the well-established era of chemotherapy. [48] At
present, recommendations of chemotherapy are:
• Following RT as adjuvant settings
• In Infant medulloblastoma, to defer RT, till the age of 3-years
• Autologous stem-cell rescue accompanied with high-dose chemotherapy with
• Concurrent chemotherapy with radiotherapy
• As a salvage therapy in cases of relapsed of recurrent medulloblastoma.
Box 1.
Chemotherapy regimens (adjuvant) in MB children >3 years of age [49, 36].
A detailed discussion about the chemotherapy and late effects of radio-
chemotherapy, management of adverse effects are outside the scope of this chapter.
It is recommended and important to havemultidisciplinary follow-up with pediatric
radiation oncologists and endocrinologists.
7. Follow up
Follow up counseling is mandatory prior to initiation of treatment. MRI brain
may be performed every three months and MRI spine may be obtained every six
months in standard risk category of standard risk patients for the initial two years.
These two investigations can be performed every 6 months up to five years, and
then repeated every year. In high-risk group, MRI of whole brain and spine may be
repeated every three months for the initial two years. Thorough clinical examina-
tion with every visit is necessary. In case of pediatric or adolescence groups follow-
ing radiotherapy, neuroendocrine follow-up with evaluation of serum hormonal
levels should be performed every six months.
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